Adaptogens for Stress 2026: ashwagandha, rhodiola, reishi - which one to choose?

Anxiety disorders are currently the most common mental disorder in the world: in 2021, 359 million people had them (WHO). Interest in adaptogens, which are plants and fungi that help the body cope with stress, is therefore growing. The problem is that the three most commonly mentioned substances have extremely different quality of evidence, different times of administration, and different contraindications. This article compares ashwagandha, rhodiola, and reishi based on what clinical trials have actually shown, not what the label promises. You will find doses from specific studies, a selection scheme according to symptoms, a comparison of real prices in the u Bucha store with a conversion to daily servings, and a list of situations in which none of these substances should be used.

KEY INFORMATION
• Ashwagandha has the strongest data: cortisol decreased by 27.9% compared to 7.9% in placebo (Chandrasekhar 2012).
• Rhodiola affects fatigue and attention, not sleep (Olsson 2009).
• Reishi was rated in the GRADE assessment as having very low quality evidence (Jafari 2025).
• None of these substances are safe during pregnancy or breastfeeding (NCCIH).
• The store has rhodiola only in blends.

What are adaptogens and how do they affect the HPA axis?

An adaptogen is a plant or fungal substance that is supposed to increase the body's non-specific resistance to stress, rather than eliminate a single symptom. The concept was introduced in the 1960s by Soviet pharmacologist Nikolai Lazarev and developed by Israel Brekhman. Modern molecular justification was gathered by Panossian and Wikman in a review published in Pharmaceuticals in 2010 (Panossian i Wikman, 2010).

This review links the protective effects of adaptogens to the regulation of homeostasis through several pathways simultaneously. It mentions the hypothalamic-pituitary-adrenal axis, heat shock proteins HSP70, JNK1 kinase, the transcription factor FOXO, as well as cortisol and nitric oxide. The authors also summarize what human trials have shown: an anti-fatigue effect that enhances cognitive performance in the context of stress and fatigue, with a particular improvement in attention.

It is worth noting what is not included in this description. There is no sedation or suppression of anxiety responses, as provided by GABA-A receptor agonism. An adaptogen does not shut down the response to a stressor; it is supposed to shorten the time it takes to return to balance after the stressor has passed. That is why the effect is subtler than that of a sedative medication and why it is harder to notice in the first week.

A practical conclusion for the buyer is that the question 'do adaptogens work' is poorly posed. Each substance in this group has its own molecular profile, its own dose from studies, and its own set of limitations. The three substances discussed below have been placed in one marketing category, but in the laboratory, they have less in common than a common shelf in a store suggests.

It is also important to remember what these products are formally. An adaptogen is not a legal category: in Poland and throughout the EU, they are sold as dietary supplements, so the manufacturer registers the product and is responsible for safety and label compliance, but does not have to prove efficacy as with a medication. That is why the data on which this article is based comes from scientific works, not from marketing materials. The label states what is in the package; whether it works is determined by clinical trials or their absence.

Ashwagandha, rhodiola, or reishi: how do they differ?

They differ in everything except the marketing category: origin, biological class, active compounds, time of administration, and quality of evidence. Ashwagandha is a nightshade plant, rhodiola is a stonecrop, and reishi is a fungus. Ashwagandha has undergone a randomized trial measuring serum cortisol, rhodiola has several trials on fatigue and attention, while reishi has a meta-analysis where the certainty of evidence was rated as very low.

The table below compares what can be directly compared. The doses are given as used in the studies cited in this article, not as suggested by supplement manufacturers.

One note about the dosage column before you read it. Milligrams from different rows are not interchangeable, as they describe different things. With ashwagandha, we are talking about an extract standardized for the percentage of withanolides; with rhodiola, it’s about the SHR-5 extract standardized for rosavins and salidroside; with reishi, it’s about the fruiting body powder or extract, across a very wide range of doses. That’s why the range for reishi looks absurdly wide: a meta-analysis collected studies from 200 mg to over 11 grams daily, as they used different raw materials and extraction methods.

Why does ashwagandha have the strongest clinical evidence?

Because it is the only one of the three that has a randomized trial with a hard endpoint measured in blood. In the study by Chandrasekhar and colleagues, 64 individuals with chronic stress took one capsule twice daily for 60 days. The capsule contained 300 mg of highly concentrated, full-spectrum root extract, referred to in the paper as KSM-66 (Indian Journal of Psychological Medicine, 2012).

The results are numerically presented in this paper. Serum cortisol decreased by 27.9% from baseline in the ashwagandha group, and by 7.9% in the placebo group; the difference between groups was significant. On the Perceived Stress Scale, the reduction was 44.0% compared to 5.5% in placebo. Adverse effects in both groups were mild and comparable, and no serious events occurred.

The second layer of evidence is a systematic review with a meta-analysis covering 20 studies and 1249 participants (Zhu i wsp., 2026). Ashwagandha improved memory (SMD 0.52), attention and processing speed (SMD 0.29), as well as executive functions. On the physical side, it raised testosterone (SMD 0.33) and muscle strength (SMD 0.58), with strength gains occurring only in physically active individuals (SMD 1.03), not in those who were untrained. It had no effect on body weight and body fat percentage.

This is quite a lot for a herbal raw material, but it's worth reading these numbers carefully. We are still talking about a standardized effect size, not about symptom remission, and the NCCIH notes that many studies on ashwagandha had small sample sizes and used different preparations. Separate studies on sleep, including the works of Lopresti and Salve from 2019, are discussed in the text about ashwagandzie na sen i stres.

How to dose ashwagandha and when to take it?

The dose replicating the protocol from the Chandrasekhar study is 600 mg of standardized extract daily, divided into two doses of 300 mg, for eight to twelve weeks. This is the most commonly repeated scheme and the only one that can be directly linked to the measured decrease in cortisol. Lower doses, around 250-300 mg daily, appear in studies on sleep and anxiety.

Timing matters. Ashwagandha has a calming profile, so if you’re taking only one dose a day, evening is more sensible than morning. With a full 600 mg, it’s more convenient to split the dose into morning and evening, just like in the cited trial, where capsules were administered twice daily.

Standardization is a separate issue, because without it, the number of milligrams on the label means nothing. Powdered root typically contains a fraction of a percent of withanolides, while standardized extracts declare 5% or more. The Polish Dietary Supplements Team indicated an upper limit of 10 mg of withanolides in the recommended daily portion of the supplement, which corresponds to 200 mg of raw material per day with a 5% extract. This number can be surprising for those aiming for 600 mg from the clinical study, as dietary supplements in Poland are by definition more cautious than research preparations.

The NCCIH restricts the time recommendation even more: it states that ashwagandha may be safe for short-term use, up to three months, and there is no data on long-term safety. This provides a good justification for a cycle with a break, stronger than popular stories about receptor saturation.

What have studies on rhodiola rosea really shown?

Rhodiola has three frequently cited trials, and it’s worth separating them, as they regularly blend into one in Polish internet discussions. The first is the Shevtsov study from 2003 published in Phytomedicine: 161 cadets aged 19-21, a single dose of SHR-5 extract, either two capsules or three, which is 370 mg or 555 mg (Phytomedicine, 2003). The anti-fatigue index was 1.0385 and 1.0195 in the groups with the preparation compared to 0.9046 in placebo, with p below 0.001. The higher dose was not better than the lower one.

The second is Darbinyan and colleagues from 2000: 56 young doctors during night shifts, a low dose of SHR-5 once daily for two weeks in an alternating schedule (Phytomedicine, 2000). Improvement in the fatigue index was significant in the first two-week period, and no adverse effects were reported.

The third is Olsson and colleagues from 2009 in Planta Medica: 60 individuals with stress-related fatigue, 576 mg of SHR-5 daily for 28 days (Planta Medica, 2009). Compared to placebo, significant results were found on the Pines burnout scale and some attention indicators in the CCPT II test. The cortisol response to awakening also changed.

We noticed during the source verification for this update that the study on night-shift doctors is sometimes attributed to Olsson, and the study on cadets is described as lasting twenty days. These are two different papers and two different protocols. The previous version of this entry repeated both inaccuracies. However, the overall picture from the 2022 review remains encouraging for symptoms related to stress, fatigue, and burnout (Ivanova Stojcheva i Quintela, 2022). We break down the standardization of the SHR-5 extract and the differences between species of rhodiola in a separate text about rhodiola rosea.

How to dose rhodiola and why not in the evening?

The range from studies is approximately 370-576 mg of standardized extract daily, and in the Darbinyan protocol, an effective dose was clearly lower, administered once a day for two weeks. Since in the Shevtsov study, 555 mg did not perform better than 370 mg, it makes sense to start from the lower end of the range and only increase if nothing happens after two weeks.

The time of day is determined by the profile of action. All three trials measured cognitive performance and fatigue, not sleep, and the preparation was administered during active hours. Rhodiola taken late in the afternoon can prolong falling asleep, so it is reasonable to set the last dose no later than early afternoon. The manufacturer of one of the oil macerates states this directly in the catalog, recommending the last dose five to six hours before sleep.

Pay attention to standardization when purchasing. The SHR-5 extract used in all three studies was a standardized raw material, and without the stated content of rosavin and salidroside, it is impossible to compare two labels. In the store catalog, declarations take the form of the abbreviation DER, for example, 10:1, which indicates the concentration of the extract but not the content of active compounds.

Caution is warranted for individuals taking serotoninergic medications. Rhodiola is sometimes described as a raw material with potential interactions with this group, and when used concurrently with SSRIs, the decision should be made by the attending physician, not the supplement seller.

The form of administration also makes a difference, although less than the price suggests. A capsule with powdered extract provides a dose measured by the manufacturer. The oil macerate is dosed in drops, and the content of the raw material is then given as a daily dose, usually fifteen drops, not for a single drop. Gummies are the most convenient and least concentrated of all three formats. In none of these variants should you compare the mass of the product, only the declared mass of the extract in the daily dose, as that is the only number that can be compared with the research protocol.

What is known about reishi, and what is still unknown?

It is known what reishi is made of, but it is unknown whether this translates into a measurable effect in humans. A review from 2025 lists triterpenoids, polysaccharides, and peptides as active fractions, stating that solid clinical studies are needed (Eira i wsp., 2025). This statement conveys more about the state of knowledge than the entire rest of the marketing for this mushroom.

The most concrete answer comes from a meta-analysis with a GRADE assessment, covering 17 randomized studies and 971 participants, with doses ranging from 200 to 11,200 mg daily and durations from one week to 24 weeks (Jafari i wsp., 2025). Four results were significant: a decrease in BMI by 0.43, a decrease in creatinine by 0.14, an increase in glutathione peroxidase by 2.29, and a decrease in heart rate by 3.92 beats per minute.

Equally important is what was not found. No effect was demonstrated on body fat, waist circumference, blood pressure, fasting glucose, lipid profile, inflammatory markers, or liver enzymes. The authors summarize that the certainty of evidence for all endpoints was very low.

What does this mean for a person under stress? That reishi currently has no clinical data comparable to ashwagandha or rhodiola, and its attributed sedative or anxiolytic effects are mainly based on animal models and tradition. The decrease in heart rate is interesting here, as it points towards the expected calming effect, but it is a single result with very low certainty. If you choose reishi, you are selecting a raw material with the least documented effects of the three.

Which adaptogen fits your symptom profile?

The choice should be based on which symptom is dominant, as the three raw materials were studied in three different situations. Ashwagandha was studied in individuals with chronic stress and cortisol levels were measured. Rhodiola was studied in people fatigued from mental work and attention was measured. Reishi was studied with metabolic points, not stress.

If tension persists for weeks, there are difficulties falling asleep despite fatigue, and irritability at the end of the day, the protocol closest to the data is ashwagandha at the dose from the study, taken in the evening or in two doses. It is the only one of the three for which a decrease in stress hormone was measured, not just well-being.

If mental fatigue, decreased attention, and working at night or shift work dominate, you are closer to rhodiola taken in the morning. You can most faithfully replicate the Darbinyan protocol by taking one low dose daily on load days, rather than increasing the dose to the maximum.

If you are looking for something for sleep or immunity, the honest answer is: reishi is the least documented option and should be treated as a supplement, not a solution. It is also worth distinguishing between two situations that popular guides confuse: stress with arousal and burnout with exhaustion are different states, and a stimulating raw material in the first case usually makes things worse. None of these three raw materials can replace sleep, regular meals, or exercise, and this cannot be bypassed with a dose. We gathered raw materials outside of this trio, where cortisol was measured directly, in the text about suplementach na stres i kortyzol.

How to check this on yourself without guessing? Change one thing at a time and give it four weeks. If you start with ashwagandha, do not add melatonin or a new evening ritual in the same week, as you will not be able to distinguish what worked. Note two simple things: how long it takes you to fall asleep and how you assess your energy around noon. This will be enough to see a trend after a month, and it also protects against the most common scenario where a second preparation is added after two weeks, and after four weeks, it is no longer clear which of them changed anything.

What does the store u Bucha really have on the shelf?

On August 8, 2026, we reviewed all 386 items in the store, along with their descriptions. Ashwagandha appears in the names of five products and in the composition of nineteen. Reishi has three entries in the name and sixteen in the composition. Rhodiola has no entries in the name, but has twelve in the composition. A single-ingredient preparation with rhodiola simply does not exist in this store, although the raw material itself is present in several formulations.

Below are the items for which the manufacturer provides the content of the raw material per serving, sorted by the cost of one daily serving. Prices are from the store, as of August 8, 2026.

Which format is cheaper per serving?

The difference can be as much as forty times and is not due to the quality of the raw material, but rather the form of administration. Loose extract costs 0.12 zł per serving, a tablet 0.70 zł, and oil macerate or cocoa ranges from 3.81 to 4.97 zł. For this difference, you pay for convenience: a ready-made serving, no scale, no taste, and no measuring.

However, the conversion has its limits, and you need to know them. Loose extract is cheap but requires a jeweler's scale, as a serving of around 200 mg is an amount that cannot be measured with a teaspoon. The manufacturer only provides standardization, and the responsibility for the serving size falls on you.

The second limit concerns blends. In cocoa, chocolate, or gummies with five ingredients, the share of a single adaptogen can be small: rhodiola in the UMYSŁ W FORMIE gummies is 60 mg of extract DER 10:1, which is significantly less than the 370 mg from Shevtsov's study. You buy such a product for the convenience of a daily ritual, not to replicate a research protocol. Single-ingredient preparations can be found in the category supplements, a surowce sypkie w kategorii herbs.

Is it worth combining adaptogens with CBD?

These are two separate mechanisms and two separate qualities of evidence, so combining them is allowed, but without promises. The most frequently repeated number regarding CBD and sleep comes from a retrospective case series from a psychiatric clinic: in 48 out of 72 adults, or 66.7%, sleep outcomes improved in the first month, and anxiety severity decreased in 79.2% (Shannon i wsp., 2019).

It's important to understand how this work is structured before treating it as evidence. This is a review of medical documentation, not a study with a control group or a consumer survey, and the authors themselves conclude that controlled studies are needed. Sleep outcomes in this series also fluctuated in subsequent months, unlike anxiety outcomes, which remained stable.

A sensible daily regimen looks like this: rhodiola in the morning, ashwagandha in the evening, CBD in the evening as an addition to the calming part. Combining rhodiola with CBD at the same time rarely makes sense, as one ingredient is studied as stimulating, while the other is described as calming.

Pharmacological caution is important. CBD inhibits cytochrome P450 isoenzymes involved in the metabolism of many drugs, so with ongoing pharmacotherapy, the decision to combine should be made by a doctor or pharmacist. Sublingual oils can be found in the category oils.

Also, pay attention to one more thing in the construction of that case series: CBD was administered as an addition to existing treatment, to patients in the clinic, not as a replacement. Interpreting this as meaning that the oil alone solves sleep problems is an overinterpretation that this work explicitly rejects. So if you plan a protocol with an adaptogen and CBD, treat both as an additional layer, not as a substitute for the therapy you are already undergoing.

Who should avoid adaptogens?

The list of contraindications is shorter than the list of promises, but it is firm. The American NCCIH states about ashwagandha directly: it should be avoided during pregnancy and not used while breastfeeding (NCCIH). For rhodiola and reishi, there is a lack of safety data during pregnancy, which in practice leads to the same conclusion.

The same NCCIH document advises against ashwagandha for people with thyroid and autoimmune diseases, as well as before planned surgery. It also provides a signal that appears rarely in Polish guides: cases of liver damage associated with ashwagandha supplements have been reported. They are rare, but they exist, and this is an argument against taking this raw material continuously for years.

Treat situations related to medications separately. With serotonergic drugs, caution is required with rhodiola. With anticoagulants and immunosuppressants, caution is required with reishi, whose fractions affect the immune response. With any ongoing pharmacotherapy, a conversation with a pharmacist takes a few minutes and resolves most doubts.

Children and adolescents under eighteen are the third group for which there is simply no data. The lack of data does not mean safety, only a lack of basis for any recommendation, and a dietary supplement is not a product where it is worth checking on your own.

Two situations require discontinuation without waiting for the next serving. The first is a planned procedure: the NCCIH explicitly mentions the preoperative period, and the surgeon and anesthesiologist should be informed about any supplement two weeks before the date. The second is liver symptoms during ashwagandha use, such as jaundice, dark urine, persistent nausea, or pain in the right upper quadrant. This is a rare but documented situation, so the response should be to discontinue and contact a doctor, not to wait it out.

What mistakes do buyers most often make?

The first mistake is comparing milligrams without standardization. Powdered root and extract standardized to 5% withanolides are two different raw materials, and 500 mg of one and 500 mg of the other can differ by several times in the content of active compounds. A label without a stated percentage or without a DER indicator does not allow for any comparison.

The second mistake is expecting an effect within a week. With ashwagandha, a measured decrease in cortisol occurred after 60 days, not after seven. With rhodiola, it can be quicker, as in a study on cadets, the effect appeared after one dose, but we are talking about the ability to perform mental tasks under fatigue, not about restructuring the stress response.

The third mistake is buying a blend with ten ingredients instead of a single-ingredient preparation. To gather 600 mg of ashwagandha from such a formula, you would need to consume several servings at once, which is rarely a good idea with the other ingredients. The blend is convenient and pleasant, but it does not replicate any research protocol.

The fourth mistake is overlooking the certificate of analysis. The COA document for a specific batch shows the actual content of active compounds, microbiological purity, and absence of heavy metals. A manufacturer who does not provide it leaves you with a marketing declaration instead of data. The fifth mistake is the simplest: counting on a supplement to make up for five hours of sleep.

The sixth mistake occurs after purchase and is the hardest to notice. It involves assessing the effect after the first few days, when it is mainly expectation that is at play. In Olsson's study, improvement occurred after 28 days in both groups, including the placebo group, and only comparison between groups showed what should be attributed to the extract itself. Your own feeling after a week has exactly the same weakness: there is nothing to compare it to. Therefore, a sensible unit of assessment is a month, not a day, and a note, not a memory.

Summary: which adaptogen to choose in 2026?

If you had to choose one raw material based on evidence rather than popularity, it would be ashwagandha. It has a randomized trial measuring serum cortisol, a meta-analysis of twenty studies involving 1249 people, and clearly defined contraindications. It also has the most specific protocol: 600 mg of standardized extract daily for eight to twelve weeks, with the caveat that the Polish limit for dietary supplements is 10 mg of withanolides per day.

Choose rhodiola when the issue is mental fatigue and decreased attention, rather than tension and sleep. The data here is weaker than for ashwagandha, but consistent across three independent trials, and the effective dose is lower than what most labels suggest. In the morning, not in the afternoon.

Consider reishi as an addition. A meta-analysis with GRADE assessment yielded significant results in four points, but the certainty of the evidence was deemed very low, and no impact on inflammatory markers was demonstrated at all. This is a raw material with a long tradition and a short list of hard data.

Finally, a practical point that arises from reviewing the catalog: in this store, you can only buy rhodiola as an ingredient in a blend, as there is no single-ingredient preparation with this raw material. You can buy ashwagandha in both variants, from loose extract for 6 PLN to capsules with oil macerate for 119 PLN. This price difference reflects convenience and form, not potency.

Frequently Asked Questions

What is the difference between an adaptogen and a regular supplement?

An adaptogen is a substance that is supposed to increase non-specific resistance to stress, rather than eliminate a single symptom. The review by Panossian and Wikman from 2010 links this action to the regulation of the hypothalamic-pituitary-adrenal axis and the heat shock proteins HSP70. A regular supplement fills a deficiency, while an adaptogen modulates the response to stress.

How long does it take to see the effects of an adaptogen?

It depends on the substance. Rhodiola improved cognitive performance after just one dose in a study of 161 cadets from 2003. Ashwagandha needed 60 days to reduce cortisol by 27.9% compared to 7.9% in the placebo group. Clinical trials for reishi lasted from one week to 24 weeks.

Can you combine ashwagandha, rhodiola, and reishi?

Yes, but not in one dose at the same time. Rhodiola has a stimulating profile and was studied in the morning, while ashwagandha and reishi were taken in the evening. A sensible arrangement is to take rhodiola in the morning and ashwagandha in the evening. Blends with several substances rarely provide doses close to those in clinical trials.

Will adaptogens replace anxiolytic or antidepressant medications?

No. They are dietary supplements, not registered medications for treating depression or anxiety disorders. Discontinuing SSRIs or benzodiazepines without consultation is dangerous. Rhodiola is additionally described as a substance that may interact with serotonergic medications, so combining them requires a conversation with the attending physician.

Are adaptogens safe during pregnancy and breastfeeding?

No. The American NCCIH states explicitly that ashwagandha should be avoided during pregnancy and not used while breastfeeding. The same document advises against it for individuals with thyroid and autoimmune diseases and before surgery. There is simply a lack of safety data for rhodiola and reishi during pregnancy.

How do adaptogens compare to CBD for sleep issues?

They operate through separate mechanisms and have different quality data. In a retrospective series of 72 psychiatric clinic patients, sleep outcomes improved in the first month for 66.7% of those taking CBD, but the authors themselves note that controlled studies are needed. Ashwagandha has undergone a randomized trial measuring cortisol.

Does the u Bucha store have products with rhodiola?

Yes, although none have rhodiola in their name. In the catalog checked on August 8, 2026, rhodiola appears in the composition of twelve items: in oil macerates from Aura Care, in gummies, in adaptogenic coffees and chocolates, and in Shroomix cocoa. The store does not carry a single-ingredient product with rhodiola.

We have gathered ready-made preparations with ashwagandha and blends with rhodiola or reishi in the category supplements, and chewable versions in the category jelly candy.

The article is informational and educational in nature and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-08